盐酸曲美他嗪治疗微血管心绞痛60例疗效观察

Clinical Observation on Trimetazidine in the Treatment of 60 Patients with Microvascular Angina

目的探讨曲美他嗪治疗微血管心绞痛的临床疗效。方法将120例微血管心绞痛患者随机分为对照组和观察组,各60例。对照组患者给予常规药物治疗,观察组患者在对照组治疗基础上加用盐酸曲美他嗪片,每次20 mg,每日3次,均连续治疗6个月。结果观察组患者未出现明显药品不良反应,缓解心绞痛的总有效率为88.33%,高于对照组的66.67%(P<0.05);观察组患者运动平板试验的总运动时间、ST段压低0.1 mV时间明显延长,ST段最大压低幅度减小,一氧化氮(NO)含量升高,内皮素-1(ET-1)和C反应蛋白(CRP)含量均下降,效果均优于对照组(P<0.05)。结论在常规治疗基础上联合曲美他嗪治疗微血管心绞痛安全、有效,能明显改善微血管心绞痛患者的生化指标,显著减少心绞痛的发病率。

Objective To investigate the clinical effect of trimetazidine for treating microvascular angina. Methods Totally 120 patients with microvascular angina were randomly divided into the control group and the observation group,60 cases in each group. The control group was given conventional drug treatment,on this basis,the observation group was given trimetazidine（ 20 mg,tid） for 6 months.Results No drug-related adverse reactions were observed in the obseruation group. The total effective rate of relieving angina pectoris in the observation group was 88. 33 %, which was higher than 66. 67 % in the control group（ P 〈 0. 05）. After treatment, in the observation group, the total exercise time of treadmill exercise testing and ST-segment depression 0. 1 mV time were significantly prolonged, the maximum amplitude of ST-segment was decreased, the NO content was increased, and the levels of ET-1 and CRP were decreased, and those effects in the observatione group were better than those in the control group（ P 〈 0. 05）. Conclusion It is safe and effective to add trimetazidine on the basis of conventional drug therapy in the treatment of microvascular angina, it can obviously improve the biochemical indexes of patients with microvascular angina and significantly reduce the incidence of angina.